Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification. [electronic resource]
Producer: 20110203Description: 812-24 p. digitalISSN:- 1573-0646
- Angiogenesis Inducing Agents -- metabolism
- Apoptosis -- drug effects
- Benzenesulfonates -- pharmacology
- Caspase 3 -- metabolism
- Cell Cycle -- drug effects
- Cell Proliferation -- drug effects
- Cell Shape -- drug effects
- Cell Survival -- drug effects
- Cyclin-Dependent Kinase Inhibitor p21 -- metabolism
- Down-Regulation -- drug effects
- Drug Synergism
- Flow Cytometry
- Gene Amplification -- drug effects
- Genistein -- pharmacology
- Humans
- Mitochondria -- drug effects
- Myeloid Cell Leukemia Sequence 1 Protein
- Neuroblastoma -- drug therapy
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Proto-Oncogene Proteins c-myc -- genetics
- Pyridines -- pharmacology
- Signal Transduction -- drug effects
- Sorafenib
- Telomerase -- metabolism
- Treatment Outcome
- Tumor Suppressor Protein p53 -- metabolism
- Up-Regulation -- drug effects
- bcl-2-Associated X Protein -- metabolism
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.